IDEXX Laboratories, Inc. $IDXX Shares Sold by Jensen Investment Management Inc.

Jensen Investment Management Inc. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,430 shares of the company’s stock after selling 5,980 shares during the quarter. Jensen Investment Management Inc.’s holdings in IDEXX Laboratories were worth $2,830,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 156.2% in the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after acquiring an additional 884,808 shares in the last quarter. Generation Investment Management LLP purchased a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $304,277,000. Norges Bank acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $221,955,000. Schroder Investment Management Group raised its position in shares of IDEXX Laboratories by 295.1% in the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after purchasing an additional 235,863 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of IDEXX Laboratories by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after buying an additional 187,967 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. UBS Group dropped their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Up 1.1%

IDEXX Laboratories stock opened at $646.53 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The firm’s 50-day moving average is $690.23 and its 200-day moving average is $667.06. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market cap of $51.63 billion, a P/E ratio of 49.47, a PEG ratio of 3.89 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.